LOGIN
Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy
April 2013
Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma
Cancer. 2012 Dec 1;118(23):5888-93Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for impl...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.